Stay updated on ALS Safety & Tolerability of Triumeq Clinical Trial
Sign up to get notified when there's something new on the ALS Safety & Tolerability of Triumeq Clinical Trial page.

Latest updates to the ALS Safety & Tolerability of Triumeq Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has been updated to reflect a new version of the study, now labeled as revision v2.15.0, and includes the addition of key collaborators such as Macquarie University and the University of Sydney. The study's focus on the safety and tolerability of CUR-101 in patients with Amyotrophic Lateral Sclerosis (ALS) has been emphasized, while previous detailed descriptions of the study's design and methodology have been removed.SummaryDifference42%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check38 days agoChange DetectedDifference0.1%
- Check45 days agoChange DetectedDifference0.1%
- Check66 days agoChange DetectedDifference0.1%
Stay in the know with updates to ALS Safety & Tolerability of Triumeq Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ALS Safety & Tolerability of Triumeq Clinical Trial page.